Search Result

Results for "

PARP1 Inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	PARP (240) Adenosine Receptor (1) Akt (5) AMPK (2) Androgen Receptor (1) Apoptosis (70) ATM/ATR (1) Aurora Kinase (1) Autophagy (12) Bcl-2 Family (5) BCRP (1) c-Met/HGFR (3) Cadherin (1) Carbonic Anhydrase (2) Caspase (15) CDK (9) Deubiquitinase (2) DNA/RNA Synthesis (11) EGFR (4) Endogenous Metabolite (6) Epigenetic Reader Domain (4) ERK (3) FABP (1) FAK (1) Fluorescent Dye (1) GLUT (1) Glutathione Peroxidase (1) GSK-3 (2) HDAC (5) Histone Methyltransferase (2) HSP (2) Hsp-targeting Chimeras (1) IAP (1) IFNAR (2) Indoleamine 2,3-Dioxygenase (IDO) (1) Influenza Virus (2) Interleukin Related (4) Isotope-Labeled Compounds (8) JNK (1) Keap1-Nrf2 (2) MDM-2/p53 (2) Microtubule/Tubulin (8) Mitophagy (5) Mixed Lineage Kinase (1) mTOR (2) NAMPT (2) Necroptosis (2) NF-κB (2) NO Synthase (1) OGT (1) P-glycoprotein (1) PANoptosis (1) PDGFR (1) PERK (2) PI3K (3) Poly(ADP-ribose) Glycohydrolase (PARG) (2) PPAR (2) PROTACs (7) Protease Activated Receptor (PAR) (1) Proteasome (1) Pyroptosis (4) Pyruvate Kinase (1) Reactive Oxygen Species (ROS) (12) Reference Standards (18) RIP kinase (1) SOD (1) STAT (2) STING (1) TGF-β Receptor (1) Thymidylate Synthase (1) TNF Receptor (1) Topoisomerase (5) Tyrosinase (1) VEGFR (3) Wnt (5) β-catenin (4)
By Research Areas:	Cancer (225) Cardiovascular Disease (7) Endocrinology (1) Infection (4) Inflammation/Immunology (19) Metabolic Disease (7) Neurological Disease (18)
Click Chemistry:	Alkynes (1)

253

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

GMP Molecules

Targets Recommended: PARP

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-16106

Talazoparib 95+ Cited Publications BMN-673; LT-673	PARP	Cancer
Talazoparib (BMN-673) is a highly potent, orally active *PARP1/2* inhibitor.Talazoparib inhibits PARP1 and PARP2 enzyme activity with K_is of 1.2 nM and 0.87 nM, respectively. Talazoparib has antitumor activity .

HY-10617A

Rucaparib 45+ Cited Publications AG014699; PF-01367338	PARP	Cancer
Rucaparib (AG014699) is an orally active, potent inhibitor of *PARP* proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib has the potential for castration-resistant prostate cancer (CRPC) research .

HY-145804

Palacaparib 1 Publications Verification AZD-9574	PPAR	Neurological Disease Cancer
AZD-9574 is a potent and brain penetrant *PARP1* inhibitor and shows >8000-fold selectivity for PARP1 compared to PARP2/3/5a/6. AZD-9574 acts by selectively inhibiting and trapping PARP1 at the sites of SSBs. AZD-9574 is an anti-cancer agent and can be used for HRD ⁺?breast cancer and advanced solid malignancies research .

HY-10617

Rucaparib phosphate 45+ Cited Publications AG-014699 phosphate; PF-01367338 phosphate	PARP	Cancer
Rucaparib (AG014699) phosphate is an orally active, potent inhibitor of *PARP* proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib phosphate is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib phosphate has the potential for castration-resistant prostate cancer (CRPC) research .

HY-12418

Stenoparib 2 Publications Verification E7449; 2X-121	PARP	Cancer
Stenoparib (E7449) is a potent *PARP1* and *PARP2* inhibitor and also inhibits TNKS1 and TNKS2, with IC₅₀s of 2.0, 1.0, ～50 and ～50 nM for PARP1, PARP2, TNKS1 and TNKS2, respectively, using ³²P-NAD ⁺ as substrate.

HY-108413

Talazoparib tosylate 95+ Cited Publications BMN 673ts	PARP	Cancer
Talazoparib tosylate (BMN 673ts) is a novel, potent and orally available *PARP1/2* inhibitor with an IC₅₀ of 0.57 nM for PARP1.

HY-102003

Rucaparib monocamsylate 35+ Cited Publications AG014699 monocamsylate; PF-01367338 monocamsylate	PARP	Cancer
Rucaparib (AG014699) monocamsylate is an orally active, potent inhibitor of *PARP* proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib monocamsylate is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib monocamsylate has the potential for castration-resistant prostate cancer (CRPC) research .

HY-13688

PJ34 hydrochloride 30+ Cited Publications	PARP	Cancer
PJ34 hydrochloride is an inhibitor of *PARP1/2* with IC₅₀ of 110 nM and 86 nM, respectively.

HY-14478

UPF 1069 1 Publications Verification	PARP	Cancer
UPF 1069 is a *PARP* inhibitor, with IC₅₀s of 8 and 0.3 μM for PARP-1 and PARP-2, respectively.

HY-170620

PARP1 PROTAC 180055 1 Publications Verification	PROTACs PARP	Cancer
PARP1 PROTAC 180055 (Compound 180055) is a selective *PARP1* PROTAC degrader (DC₅₀ in T47D and MDA-MB-231 cell lines is 180 nM and 240 nM, respectively). PARP1 PROTAC 180055 promotes ubiquitination and degradation of PARP1 as well as inhibits PARP1 enzyme activity without a noticeable DNA trapping effect. PARP1 PROTAC 180055 inhibits tumors carrying BRCA mutations with a minor impact on the growth of normal cells (Pink: PARP1 ligand (HY-10617A); Blue: E3 ligase VHL ligand (HY-125845); Black: linker (HY-W014787)) .

HY-164926

PARP1-IN-33	PARP	Neurological Disease
PARP1-IN-33 (Example 6) is a *PARP1* inhibitor (IC₅₀: 0.41 nM). PARP1-IN-33 has retinal cytoprotective effect, with an EC₅₀ of 0.02 nM (inhibition on MTS activity of H₂O₂ induced human retinal pigment epithelial cell) .

HY-108632

BYK204165 1 Publications Verification	PARP	Cancer
BYK204165 is a potent and selective *PARP1* inhibitor. BYK204165 inhibits cell-free recombinant human PARP-1 (hPARP-1) with a pIC₅₀ of 7.35 (pK_i=7.05), and murine PARP-2 (mPARP-2) with a pIC₅₀ of 5.38, respectively. BYK204165 displays 100-fold selectivity for PARP-1 .

HY-18954

NMS-P118 3 Publications Verification	PARP	Cancer
NMS-P118 is a potent, orally available, and highly selective *PARP-1* Inhibitor for cancer therapy.

HY-120115

PARPi-FL Olaparib-bodipy FL	PARP Fluorescent Dye	Cancer
PARPi-FL (Olaparib-bodipy FL) is a small-molecule fluorescent inhibitor of *PARP1* that can specifically bind to *PARP1*. PARPi-FL can be used as a fluorescent imaging agent for tumor detection, diagnosis, and surgical guidance .

HY-119653

AZ9482	PARP	Cancer
AZ9482 is a triple *PARP1/2/6* inhibitor, with IC₅₀ values of 1 nM, 1 nM and 640 nM for PARP1, PARP2 and PARP6, respectively .

HY-147027

PARP-1-IN-2	PARP Caspase Apoptosis	Neurological Disease Inflammation/Immunology Cancer
PARP-1-IN-2 (compound 11g) is a potent *PARP1* inhibitor, with an IC₅₀ of 149 nM, and ADME prediction indicates it has high blood-brain barrier permeability. PARP1-IN-2 shows significantly potent anti-proliferative activity against Human lung adenocarcinoma epithelial cell line A549. PARP1-IN-2 can induce A549 cells apoptosis .

HY-136489

KU-0058948	PARP Apoptosis	Cancer
KU-0058948 is a specific and potent *PARP1* inhibitor with an IC₅₀ of 3.4 nM. KU-0058948 induces cell cycle arrest and apoptosis of primary myeloid leukemic cells and myeloid leukemic cell lines .

HY-132297A

PARP1-IN-5 dihydrochloride 1 Publications Verification	PARP	Cancer
PARP1-IN-5 dihydrochloride is a low toxicity, orally active, potent and selective *PARP-1* inhibitor (IC₅₀ =14.7 nM). PARP1-IN-5 dihydrochloride can be used for the research of cancer .

HY-114324A

rel-PROTAC PARP1 degrader	PROTACs PARP	Cancer
rel-PROTAC PARP1 degrader is the relative configuration of ROTAC PARP1 degrader (HY-114324). ROTAC PARP1 degrader is a *PARP1* degrader based on MDM2 E3 ligand. It induces significant PARP1 cleavage and programmed cell death. PROTAC PARP1 degrader at 10 μM at 24 h inhibits MDA-MB-231 cell line with an IC₅₀ of 6.12 μM.

HY-147886

PARP1-IN-11 1 Publications Verification	PARP	Cancer
PARP1-IN-11 (compound 49) is a potent *PARP1* inhibitor with IC₅₀ value of 0.082 µM. PARP1-IN-11 shows complete inhibition of PARP2 and substantially inhibits PARP3, TNKS1 and TNKS2 .

HY-161288

UKTT15	PARP	Cancer
UKTT15 (compound 6) is an allosteric inhibitor of *PARP1* .

HY-179406

PARP1-IN-49	PARP DNA/RNA Synthesis Reactive Oxygen Species (ROS) Apoptosis	Cancer
PARP1-IN-49 is a selective *PARP1* inhibitor with an IC₅₀ of 23.56 nM and a K_d of 17.78 nM. PARP1-IN-49 shows a selectivity for PARP1 over PARP2. PARP1-IN-49 leads to the induction of DNA damage, cell cycle arrest, and apoptosis. PARP1-IN-49 also increases intracellular ROS levels and inhibits cell migration. PARP1-IN-49 can be used for the research of breast cancer and ovarian cancer .

HY-172224

PARP1/CDK12-IN-1	CDK PARP	Cancer
PARP1/CDK12-IN-1 (107) is a dual inhibitor of CDK12 and *PARP1, with IC₅₀ values of 285 nM and 34 nM for CDK12 and PARP1*, respectively .

HY-174828

ATR/PARP1-IN-1	PARP ATM/ATR Apoptosis	Cancer
ATR/PARP1-IN-1 is a potent ATR and *PARP1* dual inhibitor with IC₅₀s of 17.3 nM and 0.38 nM, respectively. ATR/PARP1-IN-1 effectively reduces cell viability, induces apoptosis and DNA damage. ATR/PARP1-IN-1 significantly impairs triple-negative breast cancer (TNBC) colony formation, migration, and invasion. ATR/PARP1-IN-1 suppresses tumor growth effectively in MDA-MB-468 xenografted mice, with no significant body weight change .

HY-146336

PARP1/2/TNKS1/2-IN-1	PARP Apoptosis	Cancer
PARP1/2/TNKS1/2-IN-1 (Compound I-9) is a dual *PARP-1, PARP-2, TNKS1* and TNKS2 inhibitor with IC₅₀ values of 0.25 nM, 1.2 nM, 13.5 nM and 4.15 nM against PARP-1, PARP-2, TNKS1 and TNKS2, respectively. PARP1/2/TNKS1/2-IN-1 exhibits favorable synergistic antitumor efficacy and induces apoptosis .

HY-116218

Amelparib JPI-289 free base	PARP	Cardiovascular Disease Neurological Disease
Amelparib (JPI-289 free base) is a potent, orally active, and water-soluble inhibitor of *PARP-1. Amelparib inhibits* PARP-1 activity (IC₅₀=18.5 nM) and cellular PAR formation (IC₅₀=10.7 nM) in the nanomolar range. Amelparib is a potential neuroprotective agent. Amelparib has the potential for the research of acute ischaemic stroke .

HY-102003A

Rucaparib camsylate AG014699 camsylate; PF-01367338 camsylate	PARP	Cancer
Rucaparib (AG014699) camsylate is an orally active, potent inhibitor of *PARP* proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib camsylate is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib camsylate has the potential for castration-resistant prostate cancer (CRPC) research .

HY-175471

PARP1-IN-42	PARP	Cancer
PARP1-IN-42 (Example 43 cis-a) is a *PARP1* inhibitor with IC₅₀ <10 nM. PARP1-IN-42 can be used in cancer research .

HY-136489A

KU-0058948 hydrochloride	PARP Apoptosis	Cancer
KU-0058948 hydrochloride is a specific and potent *PARP1* inhibitor with an IC₅₀ of 3.4 nM. KU-0058948 hydrochloride induces cell cycle arrest and apoptosis of primary myeloid leukemic cells and myeloid leukemic cell lines .

HY-164475

PARP1-IN-29	PARP	Cancer
PARP1-IN-29 is an orally active *PARP-1* inhibitor with an IC₅₀ value of 6.3 nM. PARP1-IN-29, after being labeled with [18F], can be used for positron emission tomography (PET) imaging, specifically targeting *PARP-1* in tumors. PARP1-IN-29 is applicable in the fields of oncology and imaging research, particularly for detecting *PARP-1* activity in cancer .

HY-178100

PARP1-IN-45	PARP BCRP	Cancer
PARP1-IN-45 (Compound 15) is a *PARP1* inhibitor with an IC₅₀ of 17  nM. PARP1-IN-45 effectively stimulates ATPase activity of ABCG2. PARP1-IN-45 can be used for cancers like ovarian cancer research .

HY-178972

PARP1-IN-48	PARP	Infection Metabolic Disease Cancer
PARP1-IN-48 (Compound 61) is a highly selective *PARP1* (PARP1 IC₅₀ = 3 nM, PARP2 IC₅₀ = 170 nM) inhibitor. PARP1-IN-48 can be used for research on cancer, viral infections, and metabolic conditions .

HY-132297

PARP1-IN-5	PARP	Cancer
PARP1-IN-5 is a low toxicity, orally active, potent and selective *PARP-1* inhibitor (IC₅₀ =14.7 nM). PARP1-IN-5 can be used for the research of cancer .

HY-144338

PARP1/BRD4-IN-1	Epigenetic Reader Domain PARP Apoptosis DNA/RNA Synthesis	Cancer
PARP1/BRD4-IN-1 is a potent and high selective *PARP1/BRD4* inhibitor (IC₅₀s of 49 and 202 nM in PARP1 and BRD4, respectively). PARP1/BRD4-IN-1 represses the expression and activity of PARP1 and BRD4 to synergistically inhibit the malignant growth of pancreatic cancer cells .

HY-149001

PARP1-IN-9	PARP	Cancer
PARP1-IN-9 (Compound 5c) is a PARP1 inhibitor with an IC₅₀ of 30.51 nM. PARP1-IN-9 induces cell apoptosis and shows anticancer activity. PARP1-IN-9 has higher potency than Olaparib (HY-10162) .

HY-178178

PARP1-IN-46	PARP Reactive Oxygen Species (ROS) DNA/RNA Synthesis Apoptosis	Cancer
PARP1-IN-46 is a potent *PARP-1* inhibitor with an IC₅₀ of 2.4 nM. PARP1-IN-46 demonstrates remarkable anti-proliferative activity in both rat (C6) and human (U87MG) glioma cells. PARP1-IN-46 promotes PARP cleavage, triggers DNA damage, and increases ROS. PARP1-IN-46 effectively inhibits the migration, invasion and colony formation of glioma cells, and ultimately induces cell apoptosis. PARP1-IN-46 can be used to the study of glioma .

HY-178468

PARP1-IN-47	PARP	Cancer
PARP1-IN-47 (Compound 35) is a highly selective *PARP1* inhibitor (IC₅₀ <100 nM). PARP1-IN-47 blocks poly(ADP-ribosyl)ation and disrupts DNA damage repair pathways to induce tumor cell apoptosis. PARP1-IN-47 is promising for research of solid tumors and hematological malignancies .

HY-169575

PARP1-IN-36	PARP	Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
PARP1-IN-36 (compound 11) is a 4-carboxamido-isoindolinone derivative and a selective *PARP-1* inhibitor with a K_d < 0.01 μM. PARP1-IN-36 can be utilized in cancer, cardiovascular diseases, nervous system injury and inflammation research .

HY-179386

PARP1/EZH2-IN-1	PARP Histone Methyltransferase Apoptosis Pyroptosis Necroptosis Reactive Oxygen Species (ROS) PANoptosis	Cancer
PARP1/EZH2-IN-1 is a selective *PARP1* and EZH2 dual inhibitor. PARP1/EZH2-IN-1 has IC₅₀s of 28 nM, 414 nM and 74 nM for *PARP1, PARP2* and EZH2, respectively. PARP1/EZH2-IN-1 inhibits the proliferation and migration of TNBC cells (triple-negative breast Cancer cells). PARP1/EZH2-IN-1 induces PANoptosis (Apoptosis, Pyroptosis and Necroptosis), increases the level of reactive oxygen species (ROS), and activates related inflammatory pathways. PARP1/EZH2-IN-1 can be used in triple-negative breast cancer research .

HY-170972

PARP1/NAMPT-IN-2	Apoptosis PARP NAMPT	Cancer
PARP1/NAMPT-IN-2 (Compound 13j) is a dual *PARP/NAMPT* inhibitor with IC₅₀ values of 0.8 nM and 18 nM for *PARP1* and NAMPT, respectively. PARP1/NAMPT-IN-2 can inhibit the proliferation, migration and induce apoptosis of breast cancer cells. PARP1/NAMPT-IN-2 can be used for the research of triple-negative breast cancer .

HY-175482

PARP1-IN-43	PARP	Neurological Disease Cancer
PARP1-IN-43 (Compound 5350) is a blood-brain barrier (BBB) permeable *PARP1* inhibitor, with an IC₅₀ of 5 nM. PARP1-IN-43 can be used for the study of homologous recombination (HR)-deficient central nerve system (CNS) cancers .

HY-178032

PARP1-IN-44	PARP Apoptosis Reactive Oxygen Species (ROS) DNA/RNA Synthesis STING	Cancer
PARP1-IN-44, an Olaparib (HY-10162) derivative, is an orally active *PARP1* inhibitor (IC₅₀ = 0.6 nM), and also inhibits *PARP2* (IC₅₀ = 1.0 nM) and *PARP7* (IC₅₀ = 7.5 nM). PARP1-IN-44 has selective antiproliferative activity against BRCA-deficient cancer cells with minimal toxicity to normal cells. PARP1-IN-44 induces G2/M phase arrest, promotes apoptosis, elevates ROS levels, disrupts mitochondrial membrane potential. PARP1-IN-44 suppresses PARylation while increasing γH2AX accumulation. PARP1-IN-44 activates the cGAS-STING pathway, upregulating IFN-β and CXCL10 expression. PARP1-IN-44 enhancing CD8+ T cell infiltration in a CT26 tumor mouse model, demonstrating robust in vivo antitumor efficacy .

HY-10617B

Rucaparib hydrochloride AG014699 hydrochloride; PF-01367338 hydrochloride	PARP	Cancer
Rucaparib (AG014699) hydrochloride is an orally active, potent inhibitor of *PARP* proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib hydrochloride is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib hydrochloride has the potential for castration-resistant prostate cancer (CRPC) research .

HY-10617C

Rucaparib tartrate AG-014699 tartrate; PF-01367338 tartrate	PARP	Cancer
Rucaparib (AG014699) tartrate is an orally active, potent inhibitor of *PARP* proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib tartrate is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib tartrate has the potential for castration-resistant prostate cancer (CRPC) research .

HY-160417

PARP1-IN-19	PARP	Cancer
PARP1-IN-19 is a *PARP1* inhibitor with antitumor effects (CN107955001A; Embodiment 3) .

HY-178348

PARP1/c-Met-IN-2	PARP c-Met/HGFR DNA/RNA Synthesis	Cancer
PARP1/c-Met-IN-2 is a highly potent, orally active, *PARP1* (IC₅₀ = 21.8 nM) and c-Met (IC₅₀ = 30.2 nM) dual inhibitor. PARP1/c-Met-IN-2 can elevate the expression level of γH2AX, cause DNA damage. PARP1/c-Met-IN-2 exhibits remarkable anti-tumor efficacy in the Olaparib (HY-10162)-resistant HCT116 (HCT116OR) xenograft models. PARP1/c-Met-IN-2 can be used for the study of Colon Cancer .

HY-149003

PARP1-IN-10	PARP Apoptosis	Cancer
PARP1-IN-10 (compound 12c) is a no-cytotoxicity and potent *PARP1* inhibitor with an IC₅₀ value of 50.62 nM in vitro. PARP1-IN-10 causes cell cycle arrest at G2/M phase and apoptosis, and enhances the cytotoxicity of temozolomide (TMZ) .

HY-170432

PARP1-IN-34	PARP	Cancer
PARP1-IN-34 (compound 30) is a selective *PARP1* inhibitor with an IC₅₀ of 0.32 nM. PARP1-IN-34 is a subnanomolar PARP1 inhibitor with >1000-fold selectivity against *PARP2* with an IC₅₀ of 326 nM. PARP1-IN-34 shows antitumor efficacy_[1].

HY-159612

PARP1-IN-28	PARP	Cancer
PARP1-IN-28 (compound 1) is a *PARP1* inhibitor. PARP1-IN-28 can be used in the study of cancer .

HY-174442

PARP1-IN-40	PARP	Cancer
PARP1-IN-40 is a highly selectively and orally active *PARP1* inhibitor (IC₅₀: 0.19 nM for *PARP1, 26 nM for PARP2). PARP1-IN-40* kills tumor cells by inhibiting *PARP1, leading to accumulation of DNA damage. PARP1-IN-40* has high antitumor activity against BRCA mutant MDA-MB-436 cells. PARP1-IN-40 can be used in combination with chemotherapy for cancer-related research .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-113432

Nudifloramide 2PY	Alkaloids Structural Classification Other disease Classification of Application Fields Disease markers Pyridine Alkaloids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite PARP
Nudifloramide (2PY) is one of the end products of nicotinamide-adenine dinucleotide (NAD) degradation. Nudifloramide significantly inhibits poly(ADP-ribose) polymerase (PARP-1) activity in vitro .

HY-N6866

Gomisin N	Neurological Disease Classification of Application Fields Lignans Phenylpropanoids Plants Schisandraceae Schisandra chinensis (Turcz.) Baill. Inflammation/Immunology Disease Research Fields Source Classification Cancer	Apoptosis AMPK Akt PERK Keap1-Nrf2 Caspase PARP GSK-3 NO Synthase Interleukin Related
Gomisin N is an orally active lignan compound. Gomisin N can be isolated from Schisandra chinensis. Gomisin N induces Apoptosis in a variety of cells. Gomisin N activates AMPK, Akt, MAPK/ERK, Nrf2, caspase-3 and *PARP-1. Gomisin N inhibits* GSK3β, nitric oxide (NO), and proinflammatory cytokines (IL-1β, IL-6, TNF-α). Gomisin N has anti-inflammatory, antioxidant, anti-obesity, anti-diabetic, and anti-melanogenesis activities. Gomisin N has anti-tumor activity against cervical cancer and liver cancer. Gomisin N improves Alzheimer's disease .

HY-113352

7-Methylguanine	Structural Classification Natural Products Human Gut Microbiota Metabolites Classification of Application Fields Other Diseases Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite PARP
7-Methylguanine is an orally active and competitive *PARP-1* inhibitor with a K_i value of 61 μM. 7-Methylguanine is a metabolite of nucleic acids. 7-Methylguanine has anticancer activity against uterine sarcoma and colon adenocarcinoma. 7-Methylguanine is used as a probe for protein-DNA interactions .

HY-N3677

Dammarenediol II	Triterpenes Structural Classification other families Boswellia freerana Terpenoids Plants Source Classification	OGT Akt mTOR GSK-3 Reactive Oxygen Species (ROS) Apoptosis PARP MDM-2/p53
Dammarenediol II is a ginsenoside precursor . Dammarenediol II reduces the activity of O-GlcNAc transferase (OGT) and downregulates the global O-GlcNAcylation level. Dammarenediol II inhibits the phosphorylation of Akt, mTOR and GSK3β. Dammarenediol II inhibits human carboxylesterase activity, VEGF-induced ROS production, stress fiber formation and vascular endothelial cadherin disruption. Dammarenediol II promotes cell apoptosis (apoptosis), increases the levels of cleaved *PARP1* and p53, and inhibits retinal microvascular leakage. Dammarenediol II can be used in studies related to liver cancer and diabetic retinopathy .

HY-N1775

3',4'-Dihydroxyacetophenone 3,4-DHAP	Structural Classification Classification of Application Fields Pinaceae Phenols Polyphenols Picea schrenkiana Fisch. et Mey. Plants Disease Research Fields Source Classification Cancer	Tyrosinase Reactive Oxygen Species (ROS) Keap1-Nrf2 PARP Autophagy Apoptosis
3',4'-Dihydroxyacetophenone (3,4-DHAP) is a phenolic compound with oral bioavailability, possessing potent antioxidant, anti-inflammatory, anticancer and cardiovascular protective activities. 3',4'-Dihydroxyacetophenone inhibits mushroom Tyrosinase activity with an IC₅₀ of 10 μM, thereby suppressing melanogenesis . 3',4'-Dihydroxyacetophenone inhibits platelet aggregation in platelet-rich plasma. 3',4'-Dihydroxyacetophenone reduces ROS levels in human umbilical vein endothelial cells treated with high glucose, upregulates the expression of Nrf2, HO-1 and *PARP-1* in cells, and promotes the nuclear translocation of Nrf2 . 3',4'-Dihydroxyacetophenone induces autophagy and apoptosis. 3',4'-Dihydroxyacetophenone inhibits seed germination/growth in most plants. 3',4'-Dihydroxyacetophenone can be used in the research of cancer, neurodegenerative diseases, non-alcoholic steatohepatitis, diabetes, obesity, skin pigmentation disorders, and cardiovascular and cerebrovascular diseases .

HY-N2445

Flavokawain C 4 Publications Verification	Structural Classification Classification of Application Fields Piperaceae Plants Chalcones Flavonoids other families Phenols Polyphenols Piper methysticum G.Forst. Disease Research Fields Source Classification Cancer	Apoptosis Akt JNK PERK Caspase PARP MDM-2/p53 IAP Reactive Oxygen Species (ROS) SOD FABP Autophagy AMPK mTOR GLUT EGFR PI3K HSP VEGFR FAK
Flavokawain C is an orally active natural chalcone. Flavokawain C inhibits the proliferation of various cancer cells. Flavokawain C upregulates GADD153 in cancer cells, inhibits the phosphorylation of Akt and JNK, suppresses early ERK phosphorylation, activates late ERK phosphorylation, activates caspase related subtypes, induces *PARP-1* cleavage, causes upregulation of p21 and p27, downregulation of mutant p53 and anti-apoptotic IAP proteins, elevates intracellular ROS levels, reduces SOD activity, and induces apoptosis. Flavokawain C downregulates FABP4, induces autophagy in cancer cells, and activates the AMPK/mTOR pathway . Flavokawain C decreases the expression of glycolysis-related proteins GLUT1 and HK2, and inhibits glycolysis in nasopharyngeal carcinoma cells. Flavokawain C inhibits the activation of the EGFR/PI3K/Akt/mTOR signaling pathway and reduces the expression of HSP90B1. Flavokawain C inhibits angiogenesis by decreasing the expression of angiogenic proteins Ang-1 and VEGF in human umbilical vein endothelial cells. Flavokawain C increases γ-H2AX levels in cells, inhibits the phosphorylation of FAK, PI3K and AKT in cells, and induces DNA damage in cells. Flavokawain C exerts anti-tumor activity in multiple tumor xenograft mouse models. Flavokawain C is applicable to research related to colorectal cancer, colon adenocarcinoma, nephroblastoma, nasopharyngeal carcinoma and liver cancer .

HY-113432R

Nudifloramide (Standard) 2PY (Standard)	Structural Classification Natural Products Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite PARP
Nudifloramide (Standard) is the analytical standard of Nudifloramide. This product is intended for research and analytical applications. Nudifloramide (2PY) is one of the end products of nicotinamide-adenine dinucleotide (NAD) degradation. Nudifloramide significantly inhibits poly(ADP-ribose) polymerase (PARP-1) activity in vitro .

HY-N15380

4,4′-Secalonic acid D	Xanthones Animals Phenols Source Classification	PARP Reactive Oxygen Species (ROS) Caspase Apoptosis Pyroptosis
4,4′-Secalonic acid D (Compound 12) is a *PARP1* inhibitor. 4,4′-Secalonic acid D induces the accumulation of ROS and DNA damage, activates the caspase-3/GSDME pathway, and triggers apoptosis and pyroptosis of tumor cells by inhibiting *PARP1*. 4,4′-Secalonic acid D has anti-tumor activity .

HY-N14161

Diazaquinomycin A	Microorganisms Antibiotics Other Antibiotics Source Classification	Thymidylate Synthase Apoptosis
Diazaquinomycin A (DAQA), a diaza-anthracene antibiotic, is a thymidylate synthase inhibitor. Diazaquinomycin A (DAQA) induces DNA damage, cell cycle arrest, and apoptosis through cleaved-PARP .

Cat. No.	Product Name	Chemical Structure

HY-10162S

Olaparib-d5
Olaparib-d₅ (AZD2281-d₅) is the deuterium labeled Olaparib (HY-10162). Olaparib is a potent and orally active PARP inhibitor with IC₅₀s of 5 and 1 nM for PARP1 and PARP2, respectively. Olaparib is an autophagy and mitophagy activator .

HY-10162S1

Olaparib-d8
Olaparib-d₈ (AZD2281-d₈) is the deuterium labeled Olaparib (HY-10162). Olaparib is a potent and orally active PARP inhibitor with IC₅₀s of 5 and 1 nM for PARP1 and PARP2, respectively. Olaparib is an autophagy and mitophagy activator .

HY-113432S

Nudifloramide-d3
Nudifloramide-d₃ (2PY-d₃) is the deuterium labeled Nudifloramide. Nudifloramide (2PY) is one of the end products of nicotinamide-adenine dinucleotide (NAD) degradation. Nudifloramide significantly inhibits poly(ADP-ribose) polymerase (PARP-1) activity in vitro .

HY-16106S

Talazoparib-13C,d4
Talazoparib- ¹³C,d4 is ¹³C and deuterated labeled Talazoparib (HY-16106). Talazoparib is an orally active PARP 1/2 inhibitor with Ki values of 1.2 nM and 0.87 nM for inhibiting PARP1 and PARP2 enzymatic activities, respectively. Has anti-tumor activity.

HY-16106S1

Talazoparib-d4
Talazoparib-d₄ (BMN-673-d₄) is deuterium labeled Talazoparib. Talazoparib (BMN-673) is a highly potent, orally active *PARP1/2* inhibitor.Talazoparib inhibits PARP1 and PARP2 enzyme activity with K_is of 1.2 nM and 0.87 nM, respectively. Talazoparib has antitumor activity .

HY-Z0283S

Benzamide-15N
Benzamide- ¹⁵N is a ¹⁵N-labeled Benzamide. Benzamide inhibits poly(ADP-ribose) polymerase (PARP) .

HY-10162S3

Olaparib-d4-1
Olaparib-d₄-1 (AZD2281-d₄-1) is the deuterium labeled Olaparib (HY-10162). Olaparib is a potent and orally active PARP inhibitor with IC₅₀s of 5 and 1 nM for PARP1 and PARP2, respectively. Olaparib is an autophagy and mitophagy activator .

HY-10617AS

Rucaparib-d8
Rucaparib-d₈ (AG014699-d₈ ) is deuterium labeled Rucaparib. Rucaparib (AG014699) is an orally active, potent inhibitor of *PARP* proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib has the potential for castration-resistant prostate cancer (CRPC) research .

HY-W759435

Niraparib-d5
Niraparib-d₅ (MK-4827-d₅) is the deuterium labeled Niraparib (HY-10619). Niraparib (MK-4827) is a highly potent and orally bioavailable PARP1 and PARP2 inhibitor with IC₅₀s of 3.8 and 2.1 nM, respectively. Niraparib leads to inhibition of repair of DNA damage, activates apoptosis and shows anti-tumor activity .

HY-113432S2

Nudifloramide-13C,d3
Nudifloramide- ¹³C,d₃ (2PY- ¹³C,d₃) is the ¹³C- and deuterium labeled Nudifloramide (HY-113432). Nudifloramide (2PY) is one of the end products of nicotinamide-adenine dinucleotide (NAD) degradation. Nudifloramide significantly inhibits poly(ADP-ribose) polymerase (PARP-1) activity in vitro .

Cat. No.	Product Name		Classification

HY-145749

PARPYnD		Alkynes
PARPYnD is a *PARP* enzyme photoaffinity probe (AfBP) based on the triple *PARP1/2/6* inhibitor AZ9482 (HY-119653), which induces breast cancer Formation of multipolar spindles (MPS) in cells. PARPYnD inhibits PAPR wih IC₅₀ of 38 nM (PARP1), 6 nM (PARP2), 230 nM (PARP6), respectively. PARPYnD enriches recombinant PARP6 incorporated into cell lysates and inhibits PARP6 in cell-free assays, but it does not label PARP6 in intact cells .

Targets Recommended: PARP

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13990G

NVP-TNKS656 TNKS656	PPAR Apoptosis	Cancer
NVP-TNKS656 (GMP) is NVP-TNKS656 (HY-13990) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. NVP-TNKS656 is a highly potent, selective, and orally active TNKS2 inhibitor with IC₅₀ of 6 nM, and is > 300 fold selectivity against *PARP1* and *PARP2*.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

PARP1 Inhibitor

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

NaturalProducts

Isotope-Labeled Compounds

Click Chemistry

GMP Molecules

Natural
Products